Linked Life Data

11242647

Source:http://linkedlifedata.com/resource/pubmed/id/11242647

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2001-3-12
pubmed:abstractText
Combination chemotherapy of Furtulon/low-dose cisplatin (CDDP) was administered to 13 patients with unresectable advanced gastrointestinal carcinoma (including 4 cases of gastric cancer, 6 of colorectal cancer, 1 of pancreatic cancer, 1 of hepatic cancer, and 1 of esophageal cancer). All patients were unresectable due to poor performance status (PS > 3) or metastasis. They were treated with Furtulon 1,200 mg/day orally on days 1-10 followed by 4 drug-free days, every 2 weeks, and CDDP 3.5 mg/m2/day, on days 1-5 by i.v. followed by 2 drug-free days every 4 weeks repeatedly. An average of 2-3 cycles were used. Six out of 13 patients had a partial response, 5 had no change, and 2 had progressive disease. The response rate was 46% and median survival time was 320 days. After chemotherapy, there was an increase in appetite and body weight in 11 patients (85%), and the patients maintained a good performance status and quality of life. Moreover no renal dysfunction occurred after treatment with CDDP. There was no high-grade toxicity over grade 2, only slight nausea, vomiting and diarrhea. From the present study, combination chemotherapy of Furtulon/low-dose CDDP seems to be effective for patients with advanced gastrointestinal cancer, and to have improved their quality of life (QOL).
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
205-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
[Clinical evaluation of effects and improvement in quality of life from palliative therapy of combination chemotherapy with Furtulon and consecutive low-dose cisplatin in cases of unresectable advanced gastrointestinal carcinoma].
pubmed:affiliation
Dept. of Chemotherapy, People's Hospital, Beijing University, China.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract